Mapping Patient Reported Side-Effect Incidence to Degradation of Health-Related Quality of Life Dimensions in Lymphoma and Chronic Lymphocytic Leukemia
A study from the Lymphoma Coalition’s 2024 Global Patient Survey on Lymphomas & CLL
Authors: SE Kalloger¹, A Watson¹, S Sajkovski¹, N Bolaños², L Warwick²
¹ Department of Research & Information, Lymphoma Coalition, Mississauga, ON, Canada
² Management, Lymphoma Coalition, Mississauga, ON, Canada
FPN: 1867P
Introduction
Our study sought to identify treatment-related side-effect drivers of health-related quality of life (HRQoL) degradation in a large sample of patients with lymphoma or chronic lymphocytic leukemia (CLL).
Through this process, we aim to provide symptom-specific information which will yield the potential for healthcare providers to employ mitigating strategies.
5 Dimensions of Health (By EuroQOL group EQ-5D)
- Self-care
- Usual activities
- Pain / discomfort
- Anxiety / depression
- Mobility
Methods
- Indication of degradation of dimensions of HRQoL by patients through global online survey.
- Incidence of 35 side-effects related to most recent treatment, biological sex, and birth year.
- Multivariable logistic regression was used to model the incidence of degradation in HRQoL dimensions against the 37 predictors outlined.
- Variable importance measures were used to identify the top 3 contributors to changes in HRQoL dimensions.
- Odds ratios (OR) were calculated.
Results
Responses from patients (N = 5727) spanned 65 countries and 30 lymphoma subtypes.
- Median age: 64 years (range: 18–94)
- Sex: Females comprised 60% of the sample
Key Findings
The top three treatment-related side-effects that drive degradation of each EQ-5D dimension of HRQoL are expressed in odds ratios (OR).
Associated with Increased Anxiety / Depression
- Changes in sleep patterns (OR: 1.55 [1.35–1.76])
- Fatigue (OR: 1.52 [1.31–1.77])
- Younger age (OR: 0.98 [0.97–0.98])
Associated with Performance of Usual Activities Degradation
- Muscle weakness (OR: 1.84 [1.57–2.16])
- Fatigue (OR: 1.84 [1.52–2.21])
- Inability to concentrate (OR: 1.42 [1.12–1.68])
Associated with Mobility Degradation
- Muscle weakness (OR: 2.20 [1.19–2.6])
- Respiratory issues (OR: 2.04 [1.7–2.46])
- Increasing age (OR: 1.02 [1.01–1.03])
Associated with Increased Pain
- Headaches (OR: 1.66 [1.41–1.96])
- Muscle weakness (OR: 1.57 [1.34–1.84])
- Fatigue (OR: 1.48 [1.23–1.76])
Associated with Self-Care Degradation
- Pain (OR: 2.19 [1.64–2.91])
- Muscle weakness (OR: 1.85 [1.39–2.46])
- Respiratory issues (OR: 1.82 [1.7–2.46])
Conclusion
The results indicate:
- Muscle weakness was a major cause of degradation in 4/5 HRQoL dimensions.
- Fatigue contributed to degradation in 3/5 dimensions.
- Younger age was the principal driver in amplification of anxiety/depression symptoms.
These findings highlight areas where increased attention is needed to mitigate side-effects in the pursuit of improved HRQoL.
Disclosure
This study was sponsored by:
- AstraZeneca
- Eli Lilly
- Incyte
- Kite, a Gilead Company
- Johnson & Johnson Innovative Medicine
- Novartis
- Regeneron
- F. Hoffmann-La Roche Ltd
- SERB Pharmaceuticals
- Sobi – Swedish Orphan Biovitrum
- Takeda Pharmaceuticals
Acknowledgements
For further details on the LC 2022 GPS, please scan the QR code or visit:
https://lymphomacoalition.org/global-patient-survey/
Copies of this poster may not be reproduced without written permission of the authors.
Please direct any queries to the research department at Lymphoma Coalition: steve@lymphomacoalition.orgy queries to the research department at Lymphoma Coalition: steve@lymphomacoalition.org
Summary
The Lymphoma Coalition’s 2024 Global Patient Survey analyzed responses from 5,727 patients across 65 countries to identify treatment-related side-effects driving health-related quality of life (HRQoL) degradation in lymphoma and CLL.
- Major findings:
- Muscle weakness was the most frequent driver, linked to degradation in 4 out of 5 HRQoL dimensions.
- Fatigue contributed to declines in 3 dimensions.
- Younger patients were more prone to anxiety and depression.
- Key associations:
- Anxiety/Depression: Sleep changes, fatigue, younger age.
- Usual Activities: Muscle weakness, fatigue, concentration issues.
- Mobility: Muscle weakness, respiratory issues, increasing age.
- Pain: Headaches, muscle weakness, fatigue.
- Self-Care: Pain, muscle weakness, respiratory issues.
Conclusion:
Targeting muscle weakness, fatigue, and psychological symptoms should be a priority to improve HRQoL in lymphoma and CLL patients.